TECHNOLOGY FOCUS - BIOTECHNOLOGY - Preferred Method: The method (M2) involves: a1) mixing aqueous acid with the edible oil to obtain acidic mixture having pH of less than 4, b1) mixing base with the acidic mixture to obtain reacted mixture having pH of 6-9, where the mixing in steps a1) and/or b1) creates emulsion that comprises at least 60% of aqueous phase by volume in droplet size of 15-45 mu m in size, c1) mixing phospholipase enzyme, and d1) isolating the phospholipid. The method (M3) involves: (A1) (a2) providing phospholipase polypeptide; (b2) providing a composition comprising phospholipid; and (c2) contacting the polypeptide of step (a2) with the composition of step (b2) under conditions where the phospholipase hydrolyzes, breaks up or disrupts the phospholipid-comprising composition; (B1) the method of (A1), where the composition comprises phospholipid-comprising lipid bilayer or membrane; or (C1) the method of any of (A1) or (B1), where the composition comprises plant cell, bacterial cell, yeast cell, insect cell, or animal cell, where the phospholipase polypetide is encoded by isolated, synthetic or recombinant nucleic acid (polynucleotide) comprising or consisting of a nucleic acid sequence (N1): (I) encoding a polypeptide having a phosphatidylinositol-specific phospholipase C (PI-PLC) enzyme activity, and (ia) having at least greater than or equal to 75-99, or 100% sequence identity to nucleic acid sequence containing 987 base pairs of (SEQ ID NO: 5) as given in the specification, and encoding a polypeptide having at least greater than or equal to 1-30 of the amino acid changes (mutations) consisting of those given in Table 12, Table 13, Table 14 and/or Table 15 of the specification, or equivalent amino acid substitutions and/or mutations, and optionally the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection, and optionally the sequence comparison algorithm is a BLAST version 2.2.2 algorithm where a filtering setting is set to blastall -p blastp -d nr pataa -F F, and all other options are set to default; (ib) encoding a polypeptide have an amino acid sequence containing 328 amino acids (SEQ ID NO: 6) as given in the specification and having at least greater than or equal to 1-30 of the amino acid changes or substitutions (mutations) consisting of those given in Table 12, Table 13, Table 14 and/or Table 15 of the specification, and/or equivalent amino acid changes or substitutions (mutations); or (ic) hybridizes under stringent conditions to a nucleic acid comprising (SEQ ID NO: 5) and encoding a polypeptide having at least greater than or equal to 1-30 of the amino acid changes (mutations) consisting of those given in Table 12, Table 13, Table 14 and/or Table 15 of the specification, and/or equivalent amino acid changes or substitutions (mutations), where the stringent conditions comprise a wash step comprising a wash in 0.2X SSC at 65 degrees C for 15 minutes; (id) a nucleic acid comprising or consisting of the nucleic acid sequence containing 897 base pairs of (SEQ ID NO: 7) as given in the specification, 900 base pairs of (SEQ ID NO: 9) as given in the specification or 900 base pairs of (SEQ ID NO: 10) as given in the specification; or (ie) having at least greater than or equal to 75-99%, or 100% sequence identity to (SEQ ID NO: 7), (SEQ ID NO: 9) or (SEQ ID NO: 10); (II) the nucleic acid sequence of (I) encoding a polypeptide having the PI-PLC enzyme activity but lacking a native signal sequence or proprotein amino acid sequence; (III) the nucleic acid sequence of (I) or (II) encoding a polypeptide having the PI-PLC enzyme activity but lacking a native promoter sequence; (IV) the nucleic acid of (III) further comprising a heterologous promoter sequence or other transcriptional regulatory sequence; (V) the nucleic acid sequence of any of (I) to (IV) further comprising nucleic acid encoding a heterologous amino acid sequence, or further comprising a heterologous nucleotide sequence; (VI) the nucleic acid of (V), where the nucleic acid encoding the heterologous amino acid sequence comprises, or consists of, a sequence encoding a heterologous (leader) signal sequence, or tag or epitope, or the heterologous nucleotide sequence comprises a heterologous promoter sequence; (VII) the nucleic acid of (IV), (V) or (VI), where the heterologous nucleotide sequence encodes a heterologous (leader) signal sequence comprising or consisting of an N-terminal and/or C-terminal extension for targeting to an endoplasmic reticulum (ER) or endomembrane, or to a plant endoplasmic reticulum (ER) or endomembrane system, or the heterologous sequence encodes a restriction site; (VIII) the nucleic acid of (IV), (V) or (VI), where the heterologous promoter sequence comprises or consists of a constitutive or inducible promoter, or a cell type specific promoter, or a plant specific promoter, or a bacteria specific promoter; (IX) the nucleic acid of any of (I) to (VIII), where the PI-PLC activity is thermostable; (X) the nucleic acid of any of (I) to (VIII), where the PI-PLC activity is thermotolerant; (XI) a nucleic acid sequence completely complementary to the nucleotide sequence of any of (I) to (X), or the phospholipase polypeptide comprises an amino acid sequence: (Ia) (Iai) having at least greater than or equal to 75-99%, or 100% sequence identity to (SEQ ID NO: 6), and having at least greater than or equal to 1-30 of the amino acid changes or substitutions (mutations) consisting of those given in Table 12, Table 13, Table 14 and/or Table 15 of the specification, and/or equivalent amino acid changes or substitutions (mutations), where optionally the sequence identities are determined by analysis with a sequence comparison algorithm or by a visual inspection; (Iaii) having at least greater than or equal to 75-99% or 100% sequence identity to (SEQ ID NO: 8); (Ib) the polypeptide of (Ia) but lacking a native signal sequence and/or a proprotein sequence; (Ic) the polypeptide of (Ia) or (Ib) further comprises heterologous amino acid sequence or a heterologous moiety; (Id) the polypeptide of (Ic), where the heterologous amino acid sequence or heterologous moiety comprises, or consists of a heterologous (leader) signal sequence, a tag, a detectable label or an epitope; (Ie) the polypeptide of (Id), where the heterologous (leader) signal sequence comprises or consisting of an N-terminal and/or C-terminal extension for targeting to an endoplasmic reticulum (ER) or endomembrane, or to a plant endoplasmic reticulum (ER) or endomembrane system; (If) the polypeptide of any of (Ia) to (Ie), where the PI-PLC catalyzes a reaction comprising: 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate (also called PIP2, phosphatidylinositol bisphosphate)and H2O which is interconvertable to 1D-myo-inositol 1,4,5-trisphosphate (also called IP3, inositol triphosphate) and diacylglycerol; (Ig) the polypeptide of (Ia) to (If), where the PI-PLC activity is thermostable; (Ih) the polypeptide of (Ia) to (If), where the PI-PLC activity is thermotolerant; (Ii) the polypeptide of any one of (Ia) to (Ih), where: (i-i) the polypeptide is glycosylated, or the polypeptide comprises at least one glycosylation site, (ii-i) the polypeptide of (i-i) where the glycosylation is an N-linked glycosylation or O-linked glycosylation; (iii-i) the polypeptide of (i-i) or (ii-i) where the polypeptide is glycosylated after is expressed in a yeast cell; or (iv-i) the polypeptide of (iii-i) where the yeast cell is a P. pastoris or a S. pombe; (Ij) the polypeptide of any one of (Ia) to (Ii), further comprising or contained in a composition comprising at least one second enzyme, or at least one second phospholipase enzyme; or (Ik) the polypeptide of (Ij), where the second phospholipase enzyme comprises a polypeptide having amino acid sequence containing 245 amino acids of (SEQ ID NO: 2) as given in the specification and/or 281 amino acids of (SEQ ID NO: 4) as given in the specification, or at least one of their variant PLC enzymes as given in Tables 8 and 9 of the specification. The method (M4) involves (a3) providing a phospholipase polypeptide; (b3) providing a composition comprising a phospholipid; and (c3) contacting the polypeptide of step (a3) with the composition of step (b3) under conditions where the phospholipase removes or liquefies the phospholipid-comprising composition, where the phospholipase polypetide is encoded by an isolated, synthetic or recombinant nucleic acid (polynucleotide) comprising or consisting of the nucleic acid sequence (N1). The method (M5) involves (Aa) (Aaa) providing a composition comprising a phospholipase polypeptide; (Aab) providing an composition comprising a non-hydratable phospholipid; and (Aac) contacting the polypeptide of step (Aaa) and the composition of step (Aab) under conditions where the polypeptide converts the non-hydratable phospholipid to a hydratable form, where the phospholipase polypetide is encoded by an isolated, synthetic or recombinant nucleic acid (polynucleotide) comprising or consisting of the nucleic acid sequence (N1). The method (M6) involves: AI) (AIa) providing a composition comprising a phospholipase polypeptide; (AIb) providing an composition comprising a phytosterol or a triterpene; and (AIe) contacting the polypeptide of step (AIa) with the composition of step (AIb) under conditions where the polypeptide can catalyze the hydrolysis of a phospholipid in the composition; (BI) the method of (AI), where the phytosterol or a triterpene comprises a plant sterol; (CI) the method of (BI), where the plant sterol is derived from a vegetable oil; (DI) the method of (EI), where the vegetable oil comprises coconut oil, canola oil, cocoa butter oil, corn oil, cottonseed oil, linseed oil, olive oil, palm oil, peanut oil, oil derived from rice bran, safflower oil, sesame oil, soybean oil or sunflower oil; (EI) the method of any of (AI) to (DI), further comprising use of nonpolar solvents to quantitatively extract free phytosterols and phytosteryl fatty-acid esters; or (FI) the method of (EI), where the phytosterol or a triterpene comprises beta -sitosterol, campesterol, stigmasterol, stigmastanol, beta -sitostanol, sitostanol, desmosterol, chalinasterol, poriferasterol, clionasterol or brassicasterol, where the phospholipase polypetide is encoded by isolated, synthetic or recombinant nucleic acid (polynucleotide) comprising or consisting of the nucleic acid sequence (N1). The method (M7) involves (A'1) (A2a) providing a composition comprising a phospholipase polypeptide; (A2b) providing a composition comprising oil or fat comprising phospholipid; and (A2c) contacting the polypeptide of step (A2a) with the composition of step (A2b) under conditions where the polypeptide can catalyze the hydrolysis of a phospholipid in the composition; (B'1) the method of (A'1), where the polypeptide is in a water solution that is added to the composition; (C'1) the method of (B'1), where the water level is 0.5-5%; (D'1) the method of any of (A'1) to (C'1), where the process time is less than 2 hours; (E'1) the method of any of (A'1) to (C'1), where the process time is less than 60 minutes; (F'1) the method of any of (A'1) to (C'1), where the process time is less than 30 minutes, less than 15 minutes, or less than 5 minutes; (G'1) the method of any of (A'1) to (F'1), where the hydrolysis conditions comprise a temperature of 25-70 degrees C; (H'1) the method of any of (A'1) to (G'1), where the hydrolysis conditions comprise use of caustics; (I'I) the method of any of (A'1) to (H'1), where the hydrolysis conditions comprise a pH of 3-10; (J'1) the method of any of (A'1) to (I'1), where the hydrolysis conditions comprise addition of emulsifiers and/or mixing after the contacting of step (A'1)(A2c); (K'1) the method of any of (A'1) to (J'1), comprising addition of an emulsion- breaker and/or heat or cooling to promote separation of an aqueous phase; (L'1) the method of any of (A'1) to (K'1), comprising degumming before the contacting step to collect lecithin by centrifugation and then adding PLC, PLC and/or PLA to remove non-hydratable phospholipids; (M'1) the method of any of (A'1) to (L'1), comprising water degumming of crude oil to less than 10 ppm phosphorus for edible oils and subsequent physical refining to less than 50 ppm phosphorus for biodiesel oils; or (N'1) the method of any of (A'1) to (M'1), comprising addition of acid to promote hydration of non-hydratable phospholipids, where the phospholipase polypetide is encoded by an isolated, synthetic or recombinant nucleic acid (polynucleotide) comprising or consisting of the nucleic acid sequence (N1). The method (M8) involves (aal) providing composition comprising phospholipase polypeptide; (bb1) providing composition comprising phospholipid-containing fat or oil; and (cc1) contacting the polypeptide of step (aa1) and the composition of step (bb1) under conditions where the polypeptide can catalyze the hydrolysis of a phospholipid in the composition, where the phospholipase polypetide is encoded by an isolated, synthetic or recombinant nucleic acid (polynucleotide) comprising or consisting of the nucleic acid sequence (N1). The method (M9) involves (aa2) providing composition comprising phospholipase polypeptide; (bb2) providing composition comprising oil or fat; and (cc2) contacting the polypeptide of step (aa2) and the composition of step (bb2) under conditions where the polypeptide can catalyze the hydrolysis of a phospholipid in the oil or fat, where the phospholipase polypetide is encoded by an isolated, synthetic or recombinant nucleic acid (polynucleotide) comprising or consisting of the nucleic acid sequence (N1). The method (M10) involves (A-1) (A-1a) providing composition comprising phospholipase polypeptide; (A-1b) providing composition comprising phospholipid; and (A-1c) contacting the polypeptide of step (A-1a) with the composition of step (A-1b) before, during or after the physical refining; (B-1) the method of (A-1), where the polypeptide is added before physical refining and the composition comprising the phospholipid comprises plant and the polypeptide is expressed transgenically in the plant, the polypeptide isadded during crushing of seed or other plant part, or, the polypeptide is added following crushing or prior to refining; (C-1) the method of (A-1), where the polypeptide is added during the physical refining; (D-1) the method of (A-1), where the polypeptide is added after physical refining: in an intense mixer or retention mixer prior to separation; following a heating step; in a centrifuge; in a soapstock; in a washwater; or, during a bleaching or a deodorizing step; or (E-1) the method of any of (A-1) to (D-1), further comprising adding phospholipase A (PLA), phospholipase B (PLB), phospholipase C (PLC), phospholipase D (PLD), and/or phosphatase enzyme, where the phospholipase polypetide is encoded by isolated, synthetic or recombinant nucleic acid (polynucleotide) comprising or consisting of the nucleic acid sequence (N1). The method (M11) involves (A3) (A3a) providing composition comprising polypeptide having phospholipase activity; (A3b) providing composition comprising phospholipid; and (A3c) contacting the polypeptide of step (A3a) with the composition of step (A3b) before, during or after the caustic refining; (B3) the method of (A3), where the polypeptide is added before addition of acid or caustic; (C3) the method of any of (A3) to (B3), where the polypeptide is added during caustic refining and varying levels of acid and caustic are added depending on levels of phosphorus and levels of free fatty acids; or (D3) the method of any of (A3) to (B3), where the polypeptide is added after caustic refining: in intense mixer or retention mixer prior to separation; following heating step; in centrifuge; in soapstock; in washwater; or, during bleaching or deodorizing steps; (E3) the method of any of (A3) to (D3), where caustic refining conditions are generated by addition of concentrated solution of caustic, or where caustic refining conditions comprise use of concentrated solution of caustic more concentrated than the industrial standard of 11%, or where caustic refining conditions comprise use of concentrated solution of caustic that is 12-50% concentrated; (F3) the method of any of (A3) to (E3), where the composition comprising the phospholipid comprises a plant; (G3) the method of any of (F3), where the polypeptide is expressed transgenically in the plant; (H3) the method of any of (A3) to (G3), where the polypeptide is added during crushing of a seed or other plant part, or, the polypeptide is added following crushing or prior to refining; or (I3) the method of any of (A3) to (H3), comprising a process given in figure 10 of the specification; or the process in figure 10 of the specification, where sufficient acid is added to promote lowering of the calcium and magnesium metal content, where the phospholipase polypetide is encoded by isolated, synthetic or recombinant nucleic acid (polynucleotide) comprising or consisting of the nucleic acid sequence (N1). The method (M12) involves contacting the lipid A with a phospholipase polypeptide, where the phospholipase polypetide is encoded by isolated, synthetic or recombinant nucleic acid (polynucleotide) comprising or consisting of the nucleic acid sequence (N1). The method (M13) involves (A4) (A4a) providing composition comprising phospholipase polypeptide; (A4b) providing composition comprising phospholipid-containing fat or oil; and (A4c) contacting the polypeptide of step (A4a) and the composition of step (A4b) under conditions where the polypeptide can catalyze the hydrolysis of a phospholipid in the composition for a time sufficient to reduce gum mass and increase neutral oils; (B4) the protein preparation of (A4), where the protein preparation comprises formulation comprising non-aqueous liquid composition, cast solid, powder, lyophilized powder, granular form, particulate form, compressed tablet, pellet, pill, gel form, hydrogel, paste, aerosol, spray, lotion, slurry formulation, aqueous/oil emulsion, cream, capsule, vesicle, or micellar suspension; or (C4) the method of (A4) or (B4), comprising use of high shear mixing of the composition, followed by no or low shear mixing with the at least one polypeptide of the invention having phospholipase activity to allow adequate contacting of the phospholipid substrate with the phospholipase, where the phospholipase polypetide is encoded by isolated, synthetic or recombinant nucleic acid (polynucleotide) comprising or consisting of the nucleic acid sequence (N1). The method for making (M14) biodiesel involves (A5) (a5) providing phospholipase polypeptide, where the phospholipase polypetide is encoded by isolated, synthetic or recombinant nucleic acid (polynucleotide) comprising or consisting of the nucleic acid sequence (N1); (b5) providing composition comprising lipid or alkyl ester; (c5) contacting the phospholipase polypeptide of (a5) with the composition of (b5); (B5) the method of (A5), where the composition comprising lipid or alkyl ester, or comprises oil and/or fat; or (C5) the method of (A5) or (B5), where the composition comprising lipid or alkyl ester, or comprises algae, vegetable oil, straight vegetable oil, virgin vegetable oil, waste vegetable oil, animal fat, grease, tallow, lard or yellow grease. In the method (M1), the emulsion comprises at least 60, 70, 80, 90, 93, 95, 96, 97, 98, or 99 (preferably 90)% of the aqueous phase by volume in droplet size of 20-45 (preferably 15-40) mu m in size. The droplet size is 15, 18, 20, 22, 25, 27, 29, 32, 35 or 40 mu m in size. The mixing in steps a) and/or b) is carried out with high shear mixer with a tip speed of at least 1400, 1600, 1800, 2000, 2100, 2300, 2500, 3000, or 3500 (preferably 2300) cm/s. The pH of the acidic mixture in step a) is 1-4. The acid is mixed continuously of 1 minute to 5 hours. The pH of the reaction mixture in step b) is 6-9. The base is mixed continuously of 1 minute to 5 hours. The method (M1) further involves a step of water or enzymatic degumming to obtain degummed oil. The method (M1) further involves step of enzymatic degumming. The emulsion comprises aqueous phase in average droplet size of 15-35 (preferably 15, 18, 20, 22, 25, 27, 29, or 35, 26, especially 15, 18, 20, 22, or 25, particularly 20) mu m. In the method (M2), the phospholipase enzyme is phosphatidyl-inositol specific phospholipase C. The enzyme is a polypeptide having amino acid sequence containing 298 amino acids (SEQ ID NO: 8) as given in the specification. The method (M2) further involves obtaining inositol. The phospholipase enzyme is encoded by isolated, synthetic or recombinant nucleic acid (polynucleotide) comprising or consisting of the nucleic acid sequence (N1). Preferred Components: The enzyme is selected from phospholipase A, phospholipase C, and/or phosphatidyl-inositol specific phospholipase C (preferably phospholipase C, and/or phosphatidyl-inositol specific phospholipase C, especially phospholipase C, and/or enzyme comprising (SEQ ID NO: 8), particularly polypeptide having (SEQ ID NO: 8)). The phospholipid comprises phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylinositol (PI), phosphatidic acid (PA), lysophosphatidylcholine (LPC), lysophosphatidylethanolamine (LPE), lysophosphatidylserine (LPS), lysophosphatidylinositol (LPI), lysophosphatidic acid (LP A), choline (C), ethanolamine (E), serine (S), and/or inositol (preferably phosphatidylinositol).    TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preferred Components: The edible oil is crude oil or water degummed oil. The edible oil comprises Neochloris oleoabundans oil, Scenedesmus dimorphus oil, Euglena gracilis oil, Phaeodactylum tricornutum oil, Pleurochrysis carterae oil, Prymnesium parvum oil, Tetraselmis chui oil, Tetraselmis suecica oil, Isochrysis galbana oil, Nannochloropsis salina oil, Botryococcus braunii oil, Dunaliella tertiolecta oil, Nannochloris species oil, Spirulina species oil, Chlorophycease oil, Bacilliarophy oil, acai oil, almond oil, babassu oil, blackcurrent seed oil, borage seed oil, canola oil, cashew oil, castor oil, coconut oil, coriander oil, corn oil, cottonseed oil, crambe oil, flax seed oil, grape seed oil, hazelnut oil, other nut oils, hempseed oil, jatropha oil, jojoba oil, linseed oil, macadamia nut oil, mango kernel oil, meadowfoam oil, mustard oil, neat's foot oil, olive oil, palm oil, palm kernel oil, palm olein oil, peanut oil, pecan oil, pine nut oil, pistachio oil, poppy seed oil, rapeseed oil, rice bran oil, safflower oil, sasanqua oil, sesame oil, shea butter oil, soybean oil, sunflower seed oil, tall oil, tsubaki oil, walnut oil, varieties of natural oils having altered fatty acid compositions via Genetically Modified Organisms (GMO) or traditional breading such as high oleic, low linolenic, and/or low saturated oils ( high oleic canola oil, low linolenic soybean oil or high stearic sunflower oils). The acid is selected from phosphoric acid, acetic acid, citric acid, tartaric acid, and/or succinic acid (preferably citric acid). The base is selected from sodium hydroxide, potassium hydroxide, sodium silicate, sodium carbonate, and/or calcium carbonate. The degummed oil comprises phosphorus of less than 30, less than 20, less than 15, less than 10, less than 7, less than 5 or less than 3 parts per million (ppm). EXAMPLE - No suitable example given.